Cargando…
The Effects of pH and Excipients on Exenatide Stability in Solution
Exenatide, a glucagon-like peptide-1 receptor agonist, is the active pharmaceutical ingredient in Byetta(®) and Bydureon(®), two type 2 diabetes drug products that have generics and multiple follow-up formulations currently in development. Even though exenatide is known to be chemically and physical...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8398870/ https://www.ncbi.nlm.nih.gov/pubmed/34452224 http://dx.doi.org/10.3390/pharmaceutics13081263 |
_version_ | 1783744941301694464 |
---|---|
author | Benet, Alexander Halseth, Troy Kang, Jukyung Kim, April Ackermann, Rose Srinivasan, Santhanakrishnan Schwendeman, Steven Schwendeman, Anna |
author_facet | Benet, Alexander Halseth, Troy Kang, Jukyung Kim, April Ackermann, Rose Srinivasan, Santhanakrishnan Schwendeman, Steven Schwendeman, Anna |
author_sort | Benet, Alexander |
collection | PubMed |
description | Exenatide, a glucagon-like peptide-1 receptor agonist, is the active pharmaceutical ingredient in Byetta(®) and Bydureon(®), two type 2 diabetes drug products that have generics and multiple follow-up formulations currently in development. Even though exenatide is known to be chemically and physically unstable at pH 7.5, there lacks a systematic evaluation of the impact of pH and excipients on the peptide solution stability. In this study, we established analytical methods to measure the chemical and physical degradation of the peptide in solution. Exenatide remained relatively stable at pH 4.5 when incubated at 37 °C. At pH 5.5–6.5, degradation was driven by oxidation, while driven by deamidation at pH 7.5–8.5. Significant aggregation of exenatide at pH 7.5 and 8.5 was detected by size exclusion chromatography and dynamic light scattering. Each pH value greater than 4.5 exhibited unique profiles corresponding to a loss of α-helical content and an increase in unordered structures. The addition of sugars, including mannitol, sorbitol and sucrose, conferred small protective effects against peptide aggregation when incubating at pH 7.5 and 37 °C, as measured by size-exclusion chromatography and dynamic light scattering. The results of this study will be useful for investigators developing generic exenatide products, peptide analogs and novel exenatide drug delivery systems. |
format | Online Article Text |
id | pubmed-8398870 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-83988702021-08-29 The Effects of pH and Excipients on Exenatide Stability in Solution Benet, Alexander Halseth, Troy Kang, Jukyung Kim, April Ackermann, Rose Srinivasan, Santhanakrishnan Schwendeman, Steven Schwendeman, Anna Pharmaceutics Article Exenatide, a glucagon-like peptide-1 receptor agonist, is the active pharmaceutical ingredient in Byetta(®) and Bydureon(®), two type 2 diabetes drug products that have generics and multiple follow-up formulations currently in development. Even though exenatide is known to be chemically and physically unstable at pH 7.5, there lacks a systematic evaluation of the impact of pH and excipients on the peptide solution stability. In this study, we established analytical methods to measure the chemical and physical degradation of the peptide in solution. Exenatide remained relatively stable at pH 4.5 when incubated at 37 °C. At pH 5.5–6.5, degradation was driven by oxidation, while driven by deamidation at pH 7.5–8.5. Significant aggregation of exenatide at pH 7.5 and 8.5 was detected by size exclusion chromatography and dynamic light scattering. Each pH value greater than 4.5 exhibited unique profiles corresponding to a loss of α-helical content and an increase in unordered structures. The addition of sugars, including mannitol, sorbitol and sucrose, conferred small protective effects against peptide aggregation when incubating at pH 7.5 and 37 °C, as measured by size-exclusion chromatography and dynamic light scattering. The results of this study will be useful for investigators developing generic exenatide products, peptide analogs and novel exenatide drug delivery systems. MDPI 2021-08-16 /pmc/articles/PMC8398870/ /pubmed/34452224 http://dx.doi.org/10.3390/pharmaceutics13081263 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Benet, Alexander Halseth, Troy Kang, Jukyung Kim, April Ackermann, Rose Srinivasan, Santhanakrishnan Schwendeman, Steven Schwendeman, Anna The Effects of pH and Excipients on Exenatide Stability in Solution |
title | The Effects of pH and Excipients on Exenatide Stability in Solution |
title_full | The Effects of pH and Excipients on Exenatide Stability in Solution |
title_fullStr | The Effects of pH and Excipients on Exenatide Stability in Solution |
title_full_unstemmed | The Effects of pH and Excipients on Exenatide Stability in Solution |
title_short | The Effects of pH and Excipients on Exenatide Stability in Solution |
title_sort | effects of ph and excipients on exenatide stability in solution |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8398870/ https://www.ncbi.nlm.nih.gov/pubmed/34452224 http://dx.doi.org/10.3390/pharmaceutics13081263 |
work_keys_str_mv | AT benetalexander theeffectsofphandexcipientsonexenatidestabilityinsolution AT halsethtroy theeffectsofphandexcipientsonexenatidestabilityinsolution AT kangjukyung theeffectsofphandexcipientsonexenatidestabilityinsolution AT kimapril theeffectsofphandexcipientsonexenatidestabilityinsolution AT ackermannrose theeffectsofphandexcipientsonexenatidestabilityinsolution AT srinivasansanthanakrishnan theeffectsofphandexcipientsonexenatidestabilityinsolution AT schwendemansteven theeffectsofphandexcipientsonexenatidestabilityinsolution AT schwendemananna theeffectsofphandexcipientsonexenatidestabilityinsolution AT benetalexander effectsofphandexcipientsonexenatidestabilityinsolution AT halsethtroy effectsofphandexcipientsonexenatidestabilityinsolution AT kangjukyung effectsofphandexcipientsonexenatidestabilityinsolution AT kimapril effectsofphandexcipientsonexenatidestabilityinsolution AT ackermannrose effectsofphandexcipientsonexenatidestabilityinsolution AT srinivasansanthanakrishnan effectsofphandexcipientsonexenatidestabilityinsolution AT schwendemansteven effectsofphandexcipientsonexenatidestabilityinsolution AT schwendemananna effectsofphandexcipientsonexenatidestabilityinsolution |